Loading clinical trials...
Loading clinical trials...
A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Conditions
Interventions
Lanreotide
Y-90 microspheres
Locations
3
United States
Rocky Mountain Cancer Center
Denver, Colorado, United States
Research Medical Center/HCA Midwest
Kansas City, Missouri, United States
Tennessee Oncology PLLC
Nashville, Tennessee, United States
Start Date
July 28, 2017
Primary Completion Date
May 27, 2022
Completion Date
June 10, 2022
Last Updated
December 5, 2023
NCT03206060
NCT05636618
NCT07536087
NCT01750619
NCT06228066
NCT05746208
Lead Sponsor
SCRI Development Innovations, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions